Literature DB >> 11457860

Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells.

R L Stephen1, L E Shaw, C Larsen, D Corcoran, P D Darbre.   

Abstract

This work describes a reciprocal relationship between cell density and levels of insulin-like growth factor receptors (IGFR) in MCF7 human breast cancer cells, which adds a new dimension to the mechanism of cross-talk between estrogen and insulin-like growth factors in the regulation of breast cancer cell growth. The reduced binding of both (125)I-IGF1 and alphaIR3 anti-IGFR antibody to whole cells showed that IGFR are lost from the surface of MCF7 cells as cell density increases, and this occurred irrespective of the presence or absence of estradiol. Western immunoblotting further confirmed loss of type I IGFR from MCF7 cells with increasing cell density. Long term estrogen deprivation was found to increase the levels of IGFR at all cell densities, such that after 96 weeks of estrogen deprivation, IGFR levels had become similar at the highest cell density in the absence of estradiol to the IGFR levels at the lowest cell density in the estrogen-maintained cells, and the levels of IGFR could be increased still further by estradiol. This overexpression of IGFR in the estrogen-deprived cells correlated with a reversal of response to exogenously added ligand, in that concentrations of insulin, IGFI, and IGFII that had stimulated growth of the estrogen-maintained cells became growth inhibitory to the estrogen-deprived cells. Blockade of the IGFIR with the alphaIR3 anti-IGFR antibody could partially inhibit the growth of the estrogen-deprived cells, suggesting that up-regulation of IGFR in these cells may contribute to the mechanism of adaptation to growth in steroid-deprived conditions which results in progression to estrogen independence of cell growth.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11457860     DOI: 10.1074/jbc.M105892200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

Review 1.  Cancer.

Authors:  Adda Grimberg
Journal:  Adv Exp Med Biol       Date:  2005       Impact factor: 2.622

Review 2.  Mechanisms of aromatase inhibitor resistance.

Authors:  Cynthia X Ma; Tomás Reinert; Izabela Chmielewska; Matthew J Ellis
Journal:  Nat Rev Cancer       Date:  2015-05       Impact factor: 60.716

3.  Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma.

Authors:  Domenico Alvaro; Barbara Barbaro; Antonio Franchitto; Paolo Onori; Shannon S Glaser; Gianfranco Alpini; Heather Francis; Luca Marucci; Paola Sterpetti; Stefano Ginanni-Corradini; Andrea Onetti Muda; David E Dostal; Adriano De Santis; Adolfo F Attili; Antonio Benedetti; Eugenio Gaudio
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

Review 4.  Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer.

Authors:  Vassilis Aggelis; Stephen R D Johnston
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

5.  Cancer stem-like properties of hormonal therapy-resistant breast cancer cells.

Authors:  Kanami Uchiumi; Kouki Tsuboi; Nozomi Sato; Takako Ito; Hisashi Hirakawa; Toshifumi Niwa; Yuri Yamaguchi; Shin-Ichi Hayashi
Journal:  Breast Cancer       Date:  2019-01-04       Impact factor: 4.239

6.  Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.

Authors:  Zhike Chen; Yate-Ching Yuan; Yuanzhong Wang; Zheng Liu; Hei Jason Chan; Shiuan Chen
Journal:  Breast Cancer Res Treat       Date:  2015-05-31       Impact factor: 4.872

Review 7.  Mechanisms by which IGF-I may promote cancer.

Authors:  Adda Grimberg
Journal:  Cancer Biol Ther       Date:  2003 Nov-Dec       Impact factor: 4.742

Review 8.  Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.

Authors:  Quanri Jin; Francisco J Esteva
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-25       Impact factor: 2.673

9.  GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.

Authors:  Andrea Morandi; Lesley-Ann Martin; Qiong Gao; Sunil Pancholi; Alan Mackay; David Robertson; Marketa Zvelebil; Mitch Dowsett; Ivan Plaza-Menacho; Clare M Isacke
Journal:  Cancer Res       Date:  2013-05-06       Impact factor: 12.701

10.  Carbonate apatite nanoparticles carry siRNA(s) targeting growth factor receptor genes egfr1 and erbb2 to regress mouse breast tumor.

Authors:  Snigdha Tiash; Nur Izyani Binti Kamaruzman; Ezharul Hoque Chowdhury
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.